Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1185]

Follow up from MRI imaging for low-grade prostate cancer

Dr Henk B. Luiting - University of Groningen, Groningen, The Netherlands

Follow up from MRI imaging for low-grade prostate cancer ( Dr Henk B. Luiting - University of Groningen, Groningen, The Netherlands )

Over-diagnosis of low-grade prostate cancer, good or bad?

Prof Hendrik Van Poppel - KU Leuven, Leuven, Belgium

Over-diagnosis of low-grade prostate cancer, good or bad? ( Prof Hendrik Van Poppel - KU Leuven, Leuven, Belgium )

Updates in imaging for oligometastatic disease in urological cancers

Dr Tobias Maurer - University Hospital Hamburg-Eppendorf, Hamburg, Germany

Updates in imaging for oligometastatic disease in urological cancers ( Dr Tobias Maurer - University Hospital Hamburg-Eppendorf, Hamburg, Germany )

PRIAS: Active surveillance for men with low risk prostate cancer

Prof Monique J. Roobol - Erasmus University Medical Center, Rotterdam, The...

PRIAS: Active surveillance for men with low risk prostate cancer ( Prof Monique J. Roobol - Erasmus University Medical Center, Rotterdam, The Netherlands )

EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or...

Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

EV-103: Enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )

KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC

Dr Julie Graff - Oregon Health & Science University, Portland, USA

KEYNOTE 199 cohorts 4 & 5: Enzalutamide and pembrolizumab for mCRPC ( Dr Julie Graff - Oregon Health & Science University, Portland, USA )

BCG dosing for bladder cancer: Standard frequency schedule correct

Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany

BCG dosing for bladder cancer: Standard frequency schedule correct ( Prof Oliver Grimm - Universitätsklinikum Jena, Jena, Germany )

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma

Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA

RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma ( Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA )

CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC

Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA

CHAARTED: Luminal B subtype as a biomarker of docetaxel benefit for mHSPC ( Dr Anis Hamid - Dana-Farber Cancer Institute, Boston, USA )

Integrative molecular characterisation of S/R RCC to reveal determinants of...

Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA

Integrative molecular characterisation of S/R RCC to reveal determinants of poor prognosis and response to ICIs ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )

Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or...

Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA

Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy ( Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA )

NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally...

Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom

NEO-BLADE: Nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer ( Dr Syed Hussain - University of Sheffield, Sheffield, United Kingdom )

More from ecancer